“This lower-than-500 number is all-but dispositive,” the judge stated, emphasizing the inadequacy of allegations based on a true statement rather than an unmistakably false one.
The Complex Symphony of Epidiolex: Marijuana-Derived Pharmaceutical
Epidiolex, a groundbreaking pharmaceutical derived from marijuana, gained approval from the U.S. Food and Drug Administration in 2018. Jazz Pharmaceuticals, now defending its patents for Epidiolex, initiated legal action against InvaGen, API, and others in January 2023, accusing them of patent infringement.
Legal Counterpoint: InvaGen’s March Counterclaims
In response, InvaGen launched a legal counterpoint in March, presenting over 60 counterclaims. These included challenges to the validity and enforceability of Jazz Pharmaceuticals’ Epidiolex patents.
The judge’s opinion, peculiarly void of personalization, focused solely on company names, patents, and drugs in footnotes, underscoring the legal nuances.
Counsel and representatives for the involved parties remained silent in response to requests for comment.
The Patent Symphony: Jazz Pharmaceuticals’ Defense
Jazz Pharmaceuticals, represented by William C. Baton, Sarah A. Sullivan, and Alexander L. Callo of Saul Ewing LLP, along with F. Dominic Cerrito, Eric C. Stops, Evangeline Shih, Daniel C. Wiesner, and Nicholas A. LoCastro of Quinn Emanuel Urquhart & Sullivan LLP, successfully defended its position in this legal symphony.
